Mirogab 10 mg is indicated for the treatment of neuropathic pain.

• the treatment of neuropathic pain.
• Diabetic peripheral neuropathic pain (DPNP)
• Postherpetic neuralgia (PHN)
• Peripheral neuropathic pain (PNP)

Mirogabalin belongs to the class of gamma amino acids and its derivatives. It selectively binds to the α₂δ subunits of voltage-gated calcium channels (VGCCs). This reduces calcium (Ca²⁺) influx and neurotransmission, thereby inhibiting neurotransmitter release from presynaptic nerve endings. As a result, the hyperexcitability of central nervous system (CNS) neurons is decreased.

Mirogabalin is rapidly absorbed after oral administration, with a median time to reach maximum plasma concentration of 0.5–1.5 hours. It has low plasma protein binding (approximately 25%) and an apparent volume of distribution of about 64–88 L. The drug is mainly excreted unchanged (61–72%) via the kidneys through filtration and active secretion. A small portion (13–20%) is metabolized in the liver by uridine 5'-diphospho-glucuronosyltransferase enzymes. The mean elimination half-life is 2–4.9 hours. Approximately 99% is excreted in urine and about 1% in feces.

Adult dose: The initial dose for adults is 5 mg of Mirogabalin twice daily. Then the dose is gradually increased by 5 mg at an interval of at least a week to 15 mg twice daily. The dose may be adjusted appropriately between 10 mg and 15 mg twice daily depending on ages and symptoms.

Use in Children and Adolescent: It is not known if Mirogabalin is safe and effective in children and adolescent.

Hepatic Impairment: A single 15 mg dose of Mirogabalin does not produce significant adverse reaction, in patients with mild to moderate hepatic impairment. No data available for severe hepatic impairment.

Renal Impairment: In mild renal dysfunction, the initial dose starts from 5 mg twice a day, slowly increased by 5 mg at an interval of 1 week to 10 mg. In moderate renal dysfunction, the initial dose starts from 2.5 mg twice a day, slowly increased by 2.5 mg at an interval of 1 week to 7.5 mg twice a day. In severe renal dysfunction, the initial dose starts from 2.5 mg once a day, slowly increased by 2.5 mg at an interval of 1 week to 7.5 mg once a day.

Mirogabalin is contraindicated in:

• patients with hypersensitivity to Mirogabalin.
• patients with mild to moderate hepatic & renal impairment.

The most commonly reported adverse reactions include somnolence, dizziness, edema and weight gain. The following symptoms may rarely appear as early signs of serious adverse reactions. If any of these occur, discontinue the medicine and consult a doctor immediately.

• Light headedness, near-sleep state with impaired consciousness, loss of consciousness (dizziness, somnolence, unconsciousness).
• General malaise, loss of appetite, nausea, vomiting, jaundice (liver dysfunction).

For pregnant or potentially pregnant women, use only if the therapeutic benefit outweighs the risks. Placental transfer has been observed in animal studies. Consider both therapeutic benefit and breastfeeding benefit before deciding whether to continue or discontinue breastfeeding. Animal studies have shown that it passes into breast milk.

This medicine may cause dizziness, somnolence, or loss of consciousness. Avoid operating hazardous machinery such as driving. Extra caution is required in elderly patients. This medicine may cause weight gain, blurred vision and double vision.

If allergic reactions occur, discontinue the medicine and consult a doctor. Dose adjustment is required in renal impairment. Consult a doctor before taking with other medications. Patients should avoid potentially dangerous activities. Elderly patients should be cautious about falls and fractures. Consult a doctor if blurred or double vision occurs.

Adjunct anti-epileptic drugs, Primary anti-epileptic drugs

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.